Clinical Trials

A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury

Conditions:   Osteoarthritis;   Arthritis, Rheumatoid;   Dyspepsia
Interventions:   Drug: Rabeprazole;   Drug: Rabeprazole Placebo
Sponsor:   Chinese University of Hong Kong
Completed

Thu, 10 Jun 2010 12:00:00 EDT

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Condition:   Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Intervention:   Drug: Rabeprazole
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 20 Jul 2011 12:00:00 EDT

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

Conditions:   Early Gastric Adenocarcinoma;   Adenocarcinoma, Tubular
Interventions:   Drug: rabeprazole;   Drug: placebo
Sponsors:   The Catholic University of Korea;   Janssen Korea, Ltd., Korea
Completed

Mon, 16 Feb 2009 12:00:00 EST

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

Condition:   Peptic Ulcer Hemorrhage
Interventions:   Drug: omeprazole sodium IV;   Drug: Rabeprazole
Sponsors:   The Catholic University of Korea;   Janssen Korea, Ltd., Korea
Terminated

Fri, 06 Feb 2009 12:00:00 EST

E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Condition:   Heartburn
Interventions:   Drug: rabeprazole sodium;   Other: Placebo
Sponsor:   Eisai Inc.
Completed

Wed, 12 Oct 2005 12:00:00 EDT

Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding

Condition:   Nonvariceal Upper Gastrointestinal Bleeding
Interventions:   Drug: Intravenous Omeprazole;   Drug: Oral Rabeprazole
Sponsors:   Kaohsiung Medical University Chung-Ho Memorial Hospital;   Kaohsiung Medical University
Unknown status

Fri, 13 Mar 2009 12:00:00 EDT

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Conditions:   Drug Interaction Potentiation;   Pharmacokinetics
Interventions:   Drug: Vadadustat;   Drug: Rabeprazole
Sponsor:   Akebia Therapeutics
Completed

Fri, 28 Dec 2018 12:00:00 EST

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Condition:   Esophageal Disease
Interventions:   Drug: Rabeprazole 20mg bid;   Drug: Rabeprazole 20mg qd
Sponsors:   Seoul National University Hospital;   IlDong Pharmaceutical Co Ltd
Completed

Fri, 28 Jun 2019 12:00:00 EDT

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Condition:   Heartburn
Interventions:   Drug: rabeprazole sodium;   Drug: placebo
Sponsor:   Eisai Inc.
Completed

Wed, 12 Oct 2005 12:00:00 EDT

Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole

Condition:   Refractory Reflux Esophagitis
Interventions:   Drug: Trimebutine Maleate;   Drug: rabeprazole
Sponsors:   Xijing Hospital of Digestive Diseases;   Ankang City Central Hospital;   Shaanxi Provincial People's Hospital;   Baoji Central Hospital;   Hanzhong Central Hospital
Unknown status

Thu, 08 Dec 2016 12:00:00 EST

Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: dexlansoprazole based triple therapy;   Drug: rabeprazole-based triple therapy
Sponsor:   Kaohsiung Medical University
Completed

Fri, 04 Sep 2015 12:00:00 EDT

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: rabeprazole;   Drug: standard dose rabeprazole
Sponsor:   Inje University
Withdrawn

Tue, 12 Jul 2011 12:00:00 EDT

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

Condition:   Healthy
Interventions:   Drug: Rabeprazole Sodium Tablets 20 mg;   Drug: Aciphex® Tablets 20 mg
Sponsor:   Mylan Pharmaceuticals
Completed

Tue, 01 Apr 2008 12:00:00 EDT

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole sodium;   Drug: Esomeprazole
Sponsor:   Eisai Inc.
Completed

Tue, 15 Apr 2008 12:00:00 EDT

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

Condition:   Gastrointestinal Diseases
Interventions:   Drug: IDIAZOLE 20mg DR tabs;   Drug: PARIET 20 mg DR tabs
Sponsor:   GlaxoSmithKline
Completed

Mon, 16 Nov 2015 12:00:00 EST

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole sodium;   Drug: Esomeprazole
Sponsor:   Eisai Inc.
Completed

Tue, 15 Apr 2008 12:00:00 EDT

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole sodium;   Drug: Esomeprazole
Sponsor:   Eisai Inc.
Completed

Tue, 15 Apr 2008 12:00:00 EDT

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

Condition:   Healthy
Interventions:   Drug: Rabeprazole Sodium Delayed-Release Tablets 20 mg;   Drug: Aciphex® Tablets 20 mg
Sponsor:   Mylan Pharmaceuticals
Completed

Tue, 01 Apr 2008 12:00:00 EDT

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

Condition:   Healthy
Interventions:   Drug: Rabeprazole Sodium Delayed-Release Tablets 20 mg;   Drug: Aciphex® Delayed-Release Tablets 20 mg
Sponsor:   Mylan Pharmaceuticals
Completed

Tue, 01 Apr 2008 12:00:00 EDT

Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori

Condition:   H. Pylori Infection
Interventions:   Drug: rabeprazole-based regimen;   Drug: esomeprazole^based regimen
Sponsor:   Hamamatsu University
Completed

Tue, 10 May 2016 12:00:00 EDT

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Condition:   Refractory Reflux Esophagitis
Intervention:   Drug: rabeprazole sodium
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 23 Mar 2011 12:00:00 EDT

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Condition:   Gastroesophageal Reflux Disease (GERD)
Intervention:   Drug: rabeprazole
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Completed

Mon, 10 Nov 2008 12:00:00 EST

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux
Intervention:   Drug: Rabeprazole sodium
Sponsors:   Janssen Research & Development, LLC;   Eisai Inc.
Completed

Wed, 04 Mar 2009 12:00:00 EST

Maintenance Intermittent Therapy for Symptomatic GERD Patients

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: Rabeprazole 20 mg
Sponsor:   Eisai Inc.
Completed

Wed, 14 Sep 2005 12:00:00 EDT

PPI And Food Effect Study For PF-06463922 In Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: PF-06463922;   Drug: rabeprazole
Sponsor:   Pfizer
Completed

Tue, 06 Oct 2015 12:00:00 EDT

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole sodium 5 mg;   Drug: Rabeprazole sodium 10 mg
Sponsors:   Janssen Research & Development, LLC;   Eisai Inc.
Completed

Fri, 05 Sep 2008 12:00:00 EDT

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Conditions:   Drug Interaction;   Food-drug Interaction
Interventions:   Drug: fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole;   Drug: fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Sponsor:   Hutchison Medipharma Limited
Completed

Fri, 27 Nov 2020 12:00:00 EST

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: AD-214-02;   Drug: Rabeprazole
Sponsor:   Addpharma Inc.
Completed

Tue, 10 Nov 2020 12:00:00 EST

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Condition:   Symptomatic Gastroesophageal Reflux Disease (sGERD)
Interventions:   Drug: rabeprazole sodium;   Drug: Placebo
Sponsor:   Eisai Inc.
Completed

Tue, 02 Jun 2009 12:00:00 EDT

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole ER;   Drug: Ranitidine
Sponsor:   Eisai Inc.
Completed

Fri, 06 Feb 2009 12:00:00 EST

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Drug: Rabeprazole ER;   Drug: Ranitidine
Sponsor:   Eisai Inc.
Completed

Mon, 09 Feb 2009 12:00:00 EST

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

Condition:   Reflux Esophagitis
Interventions:   Drug: Rabeprazole;   Drug: Lansoprazole
Sponsor:   Janssen Korea, Ltd., Korea
Completed

Fri, 06 Nov 2009 12:00:00 EST

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: AD-214 10/600mg;   Drug: Rabeprazole 10mg
Sponsor:   Addpharma Inc.
Completed

Fri, 31 Jul 2020 12:00:00 EDT

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

Condition:   Healthy Volunteers
Interventions:   Drug: GDC-0853;   Drug: Rabeprazole
Sponsor:   Genentech, Inc.
Completed

Mon, 25 Sep 2017 12:00:00 EDT

A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection

Condition:   Helicobacter Infections
Intervention:   Drug: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Sponsor:   American University of Beirut Medical Center
Completed

Wed, 13 Oct 2010 12:00:00 EDT

A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults

Condition:   Gastrointestinal Diseases
Interventions:   Drug: Idiazole 20mg DR tabs;   Drug: PARIET 20 mg DR tabs
Sponsor:   GlaxoSmithKline
Completed

Mon, 18 May 2015 12:00:00 EDT

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

Condition:   Healthy
Interventions:   Drug: JNJ-42847922;   Drug: Rabeprazole
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 18 Jun 2015 12:00:00 EDT

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers

Conditions:   Atrial Fibrillation;   Venous Thromboembolism
Interventions:   Drug: RABEprazole 20 Mg Oral Delayed Release Tablet;   Drug: APO-Dabigatran 150mg
Sponsors:   Population Health Research Institute;   Hamilton Health Sciences Corporation
Recruiting

Fri, 08 Nov 2019 12:00:00 EST

Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Amoxicillin;   Drug: Rabeprazole, Amoxicillin
Sponsor:   Mackay Memorial Hospital
Completed

Fri, 11 May 2018 12:00:00 EDT

Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: Rabelis DDR 50 mg Capsules;   Drug: Pariet 20 mg Enteric Coated Tablets
Sponsor:   Neutec Ar-Ge San ve Tic A.Ş
Completed

Tue, 31 Jan 2017 12:00:00 EST

Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets

Conditions:   Gastric Ulcer;   Duodenal Ulcer
Intervention:   Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Sponsor:   Taipei Veterans General Hospital, Taiwan
Unknown status

Wed, 23 Dec 2009 12:00:00 EST

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux
Interventions:   Drug: Rabeprazole sodium 5 mg;   Drug: Rabeprazole sodium 10 mg;   Drug: Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Completed

Fri, 09 Oct 2009 12:00:00 EDT

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Condition:   Gastric Cancer
Interventions:   Drug: Ilaprazole;   Drug: Rabeprazole
Sponsor:   Il-Yang Pharm. Co., Ltd.
Completed

Wed, 23 Dec 2015 12:00:00 EST

A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants

Condition:   Healthy Volunteer
Interventions:   Drug: Cobimetinib;   Drug: Rabeprazole
Sponsor:   Genentech, Inc.
Completed

Mon, 17 Jan 2011 12:00:00 EST

A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)

Condition:   Healthy
Interventions:   Drug: Idiazole 20mg DR tabs;   Drug: PARIET 20 mg DR tabs
Sponsors:   Genuine Research Center, Egypt;   GlaxoSmithKline
Completed

Mon, 22 Jun 2015 12:00:00 EDT

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

Condition:   Frequent Heartburn
Intervention:   Drug: Rabeprazole sodium
Sponsor:   Eisai Inc.
Completed

Mon, 31 Jan 2011 12:00:00 EST

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

Condition:   Healthy
Interventions:   Drug: E3810;   Drug: Aciphex (rabeprazole);   Drug: Nexium (esomeprazole)
Sponsor:   Eisai Inc.
Completed

Wed, 30 Jun 2010 12:00:00 EDT

Effects of YF476 and Rabeprazole on Gastric Function

Condition:   Hypergastrinaemia
Interventions:   Drug: YF476;   Drug: Rabeprazole
Sponsor:   Trio Medicines Ltd.
Completed

Wed, 03 Oct 2012 12:00:00 EDT

A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Condition:   Healthy
Interventions:   Drug: BMS-986165;   Drug: Rabeprazole
Sponsor:   Bristol-Myers Squibb
Completed

Fri, 07 Jun 2019 12:00:00 EDT

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: Rabeprazole 20mg, placebo dinner and bedtime;   Drug: Rabeprazole 20 mg two times, Placebo at bedtime;   Drug: Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Sponsor:   US Department of Veterans Affairs
Completed

Thu, 04 Oct 2007 12:00:00 EDT

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Conditions:   Gastroesophageal Reflux;   Heartburn
Intervention:   Drug: rabeprazole
Sponsor:   Janssen-Ortho Inc., Canada
Completed

Sun, 04 Nov 2007 12:00:00 EDT

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

Condition:   Gastroesophageal Reflux
Intervention:   Drug: rabeprazole sodium
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Mon, 12 Apr 2010 12:00:00 EDT

New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection:a Pilot Study

Condition:   Functional Dyspepsia
Interventions:   Drug: Rabeprazole and Amoxicillin;   Drug: Amoxicillin and Rabeprazole
Sponsor:   Shanghai Jiao Tong University School of Medicine
Completed

Fri, 20 Jan 2012 12:00:00 EST

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Condition:   Healthy
Interventions:   Drug: Rabeprazole sodium, 5 mg Tablets;   Drug: Rabeprazole sodium, 10 mg Tablets;   Drug: Rabeprazole sodium, 20 mg Tablets;   Drug: Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 15 Sep 2010 12:00:00 EDT

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Condition:   Healthy Participants
Interventions:   Drug: E7090;   Drug: Rabeprazole 20 mg;   Drug: Rifampin 600 mg
Sponsor:   Eisai Co., Ltd.
Active, not recruiting

Fri, 25 Sep 2020 12:00:00 EDT

Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

Conditions:   Gastroesophageal Reflux;   Pharyngeal Diseases
Intervention:   Drug: Rabeprazole Sodium
Sponsor:   Janssen Korea, Ltd., Korea
Completed

Wed, 13 Feb 2008 12:00:00 EST

Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: RAK therapy;   Drug: RBAK therapy
Sponsor:   Kaohsiung Medical University Chung-Ho Memorial Hospital
Completed

Tue, 11 Apr 2017 12:00:00 EDT

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: Rabeprazole Sodium 10mg;   Drug: Rabeprazole Sodium 20mg
Sponsors:   Yungjin Pharm. Co., Ltd.;   Seoul National University Hospital
Recruiting

Mon, 11 Jan 2021 12:00:00 EST

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions

Condition:   Healthy
Intervention:   Drug: Rabeprazole sodium 20 mg Delayed Release tablet
Sponsor:   Torrent Pharmaceuticals Limited
Completed

Thu, 21 Nov 2013 12:00:00 EST

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions

Condition:   Healthy
Intervention:   Drug: Rabeprazole sodium 20 mg Delayed Release tablet
Sponsor:   Torrent Pharmaceuticals Limited
Completed

Thu, 21 Nov 2013 12:00:00 EST

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Condition:   GERD
Interventions:   Drug: rabeprazole;   Drug: pantoprazole
Sponsor:   National Taiwan University Hospital
Completed

Tue, 20 May 2008 12:00:00 EDT

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Conditions:   Helicobacter Infections;   Bacterial Infections
Intervention:   Drug: rabeprazole sodium
Sponsor:   Janssen Cilag Pharmaceutica S.A.C.I., Greece
Completed

Thu, 22 Sep 2005 12:00:00 EDT

A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers

Condition:   Healthy
Interventions:   Drug: Rabeprazole sodium: Treatment A;   Drug: Rabeprazole sodium: Treatment B;   Drug: Rabeprazole sodium: Treatment C
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Tue, 16 Nov 2010 12:00:00 EST

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Conditions:   Gastroesophageal Reflux;   Heartburn
Intervention:   Drug: rabeprazole sodium
Sponsor:   Janssen Cilag Pharmaceutica S.A.C.I., Greece
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Condition:   Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Intervention:   Drug: Rabeprazole Sodium
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 22 Dec 2010 12:00:00 EST

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

Condition:   Esophageal Reflux
Intervention:   Drug: Rabeprazole
Sponsors:   University of Kansas;   PriCara, Unit of Ortho-McNeil, Inc.;   Eisai Inc.
Completed

Thu, 22 Sep 2005 12:00:00 EDT

A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

Conditions:   Gastroesophageal Reflux;   Heartburn
Intervention:   Drug: rabeprazole
Sponsor:   Janssen Pharmaceutica N.V., Belgium
Completed

Wed, 12 Oct 2005 12:00:00 EDT

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

Conditions:   Asthma;   Gastroesophageal Reflux Disease
Intervention:   Drug: rabeprazole
Sponsors:   Associated Scientists to Help Minimize Allergies;   Janssen Pharmaceuticals;   Eisai Inc.
Completed

Thu, 22 Sep 2005 12:00:00 EDT

ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA

Condition:   Upper Gastrointestinal Bleeding
Interventions:   Drug: Rabeprazole;   Drug: Famotidine
Sponsor:   Chinese University of Hong Kong
Completed

Wed, 03 Aug 2011 12:00:00 EDT

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

Condition:   GERD
Intervention:   Drug: rabeprazole sodium
Sponsor:   Janssen-Ortho Inc., Canada
Completed

Tue, 19 Sep 2006 12:00:00 EDT

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: rabeprazole sodium
Sponsor:   Eisai Inc.
Completed

Mon, 22 Aug 2005 12:00:00 EDT

A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn

Condition:   Gastroesophageal Reflux
Intervention:   Drug: rabeprazole and pantoprazole
Sponsors:   PriCara, Unit of Ortho-McNeil, Inc.;   Eisai Inc.
Completed

Wed, 12 Oct 2005 12:00:00 EDT

Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Levofloxacin-Amox/clav.;   Drug: Clarithromycin-Amoxicillin
Sponsor:   Buddhist Tzu Chi General Hospital
Terminated

Thu, 12 Apr 2012 12:00:00 EDT

Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions

Condition:   Gastric Lesion
Interventions:   Drug: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.;   Drug: 550 mg naproxen + placebo + 20 mg rabeprazole;   Drug: 550 mg naproxen + 300 mg rebamipide + placebo;   Drug: 550 mg naproxen + placebo + placebo
Sponsors:   Galeno Desenvolvimento de Pesquisas Clínicas;   Biolab Sanus Farmaceutica
Completed

Wed, 05 Sep 2018 12:00:00 EDT

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Condition:   Healthy
Interventions:   Drug: Palbociclib Alone;   Drug: Palbociclib + Rabeprazole
Sponsor:   Pfizer
Completed

Tue, 09 Dec 2014 12:00:00 EST

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Condition:   Healthy Volunteers
Interventions:   Drug: Vonoprazan;   Drug: Esomeprazole;   Drug: Rabeprazole sodium
Sponsor:   Takeda
Completed

Thu, 16 Jan 2014 12:00:00 EST

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Conditions:   Gastroesophageal Reflux;   Laryngitis
Intervention:   Drug: Rabeprazole 20mg twice daily
Sponsors:   Hospital Authority, Hong Kong;   The University of Hong Kong
Completed

Thu, 16 Aug 2007 12:00:00 EDT

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Condition:   Healthy Volunteer
Interventions:   Drug: Rabeprazole;   Drug: CC-92480
Sponsor:   Celgene
Completed

Thu, 26 Dec 2019 12:00:00 EST

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

Condition:   Healthy Volunteer
Interventions:   Drug: Folic Acid;   Drug: GDC-0853;   Drug: Methotrexate;   Drug: Rabeprazole
Sponsor:   Genentech, Inc.
Completed

Fri, 04 Mar 2016 12:00:00 EST

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Condition:   Functional Dyspepsia
Interventions:   Drug: Rabeprazole;   Drug: Placebo
Sponsor:   Eisai Co., Ltd.
Completed

Thu, 18 Mar 2010 12:00:00 EDT

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Condition:   Healthy Volunteer
Interventions:   Drug: Palbociclib;   Drug: Rabeprazole
Sponsor:   Pfizer
Completed

Tue, 18 Jul 2017 12:00:00 EDT

Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel

Condition:   Healthy
Interventions:   Drug: Treatment A - rabeprazole;   Drug: Treatment B - omeprazole;   Other: Treatment C - placebo
Sponsor:   Janssen Cilag S.A.S.
Completed

Mon, 05 Oct 2009 12:00:00 EDT

Surufatinib DDI With a PPI and a CYP3A Inducer

Condition:   Healthy
Interventions:   Drug: Part A;   Drug: Part B
Sponsor:   Hutchison Medipharma Limited
Completed

Wed, 12 Aug 2020 12:00:00 EDT

Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: RA5-RACM7;   Drug: RA3-RACM7;   Drug: RA7-RACM7
Sponsors:   Buddhist Tzu Chi General Hospital;   Kaohsiung Medical University
Unknown status

Thu, 29 Mar 2012 12:00:00 EDT

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Condition:   Infectious Disease
Interventions:   Drug: Acalabrutinib;   Drug: Rabeprazole
Sponsors:   AstraZeneca;   Acerta Pharma BV
Completed

Tue, 28 Jul 2020 12:00:00 EDT

A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

Condition:   Healthy
Interventions:   Drug: Rabeprazole sodium: Treatment E;   Drug: Rabeprazole sodium: Treatment C;   Drug: Rabeprazole sodium: Treatment D;   Drug: Rabeprazole sodium: Treatment A;   Drug: Rabeprazole sodium: Treatment B
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed

Mon, 23 Aug 2010 12:00:00 EDT

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

Condition:   Gastro-oesophageal Reflux
Interventions:   Drug: Esomeprazole;   Drug: Rabeprazole
Sponsor:   Janssen-Cilag Pty Ltd
Completed

Mon, 23 Apr 2007 12:00:00 EDT

Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: High-dose dual therapy (rabeprazole, amoxicillin);   Drug: Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
Sponsor:   National Taiwan University Hospital
Completed

Tue, 07 Jul 2015 12:00:00 EDT

Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: High-dose dual therapy (rabeprazole, amoxicillin);   Drug: Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
Sponsor:   National Taiwan University Hospital
Completed

Mon, 29 Jun 2015 12:00:00 EDT

Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia

Condition:   Helicobacter Pylori Infection
Intervention:   Diagnostic Test: 13C Urea Breath Test
Sponsor:   Thammasat University
Unknown status

Fri, 12 Jan 2018 12:00:00 EST

Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

Conditions:   Helicobacter Pylori Infection;   Helicobacter Gastritis;   Helicobacter-Associated Pyloric Ulcer
Intervention:   Drug: Rabeprazole
Sponsor:   Chang Gung Memorial Hospital
Unknown status

Mon, 14 Jan 2019 12:00:00 EST

Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy

Conditions:   Dyspepsia;   Chronic Gastritis;   Gastric Cancer;   Helicobacter Pylori Infection
Interventions:   Drug: Berberine;   Drug: Amoxicillin;   Drug: Rabeprazole;   Drug: Clarithromycin;   Drug: Bismuth
Sponsor:   Xijing Hospital of Digestive Diseases
Enrolling by invitation

Wed, 06 Jan 2021 12:00:00 EST

A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Condition:   Duodenal Ulcer,DU
Interventions:   Drug: Anaprazole Sodium;   Drug: Rabeprazole;   Drug: Rabeprazole Placebo;   Drug: Anaprazole Sodium Placebo
Sponsor:   Sihuan Pharmaceutical Holdings Group Ltd.
Not yet recruiting

Thu, 02 Jan 2020 12:00:00 EST

CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing

Condition:   GERD
Intervention:   Drug: rabeprazole
Sponsor:   National Taiwan University Hospital
Completed

Thu, 20 Jul 2006 12:00:00 EDT

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

Condition:   Stomach Ulcer
Interventions:   Drug: E0671;   Drug: rabeprazole sodium;   Drug: E0671 placebo
Sponsor:   Eisai Co., Ltd.
Completed

Tue, 02 Aug 2005 12:00:00 EDT

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Condition:   Cancer
Interventions:   Drug: Dabrafenib 150 mg twice a day (BID);   Drug: Rabeprazole 40 mg once daily (OD);   Drug: Rifampin 600 mg OD
Sponsor:   GlaxoSmithKline
Completed

Tue, 01 Oct 2013 12:00:00 EDT

Personalized Treatment for Refractory H Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: rabeprazole+3 antibiotics;   Drug: rabeprazole+bismuth+2 antibiotics;   Drug: rabeprazole+amox+tetr+levo
Sponsors:   Kaohsiung Veterans General Hospital.;   Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting

Fri, 11 Sep 2015 12:00:00 EDT

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

Condition:   Duodenal Ulcer
Interventions:   Drug: 5 mg ilaprazole;   Drug: 10 mg ilaprazole;   Drug: 10 mg Rabeprazole
Sponsor:   Livzon Pharmaceutical Group Inc.
Completed

Thu, 28 Jul 2016 12:00:00 EDT

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Condition:   Non-erosive Gastroesophageal Reflux Disease
Intervention:   Drug: RABEPRAZOLE SODIUM
Sponsors:   Eisai Inc.;   Eisai Limited
Completed

Wed, 14 Sep 2005 12:00:00 EDT

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Condition:   Healthy
Interventions:   Drug: Z-215 10mg;   Drug: Z-215 20mg;   Drug: Rabeprazole Sodium 10mg;   Drug: Rabeprazole Sodium 20mg
Sponsor:   Zeria Pharmaceutical
Completed

Tue, 28 Jul 2015 12:00:00 EDT

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

Condition:   Pharmacodynamic
Interventions:   Dietary Supplement: betaine hydrochloride;   Drug: Rabeprazole
Sponsor:   University of California, San Francisco
Completed

Tue, 09 Nov 2010 12:00:00 EST

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Condition:   Esophagitis, Reflux
Interventions:   Drug: Z-215 10mg;   Drug: Z-215 20mg;   Drug: Z-215 Placebo;   Drug: Rabeprazole Sodium;   Drug: Rabeprazole Sodium Placebo
Sponsor:   Zeria Pharmaceutical
Completed

Thu, 04 Jun 2015 12:00:00 EDT

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

Condition:   Reflux Esophagitis
Intervention:   Drug: Newrabell® Tablet 10mg
Sponsor:   Chong Kun Dang Pharmaceutical
Completed

Wed, 22 May 2013 12:00:00 EDT

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: Standard dose (once daily) PPI plus low-dose antidepressant;   Drug: Double dose PPI plus evening placebo;   Drug: Rabeprazole , placebo, placebo
Sponsors:   University of Arizona;   Southern Arizona VA Health Care System;   Janssen Pharmaceutica N.V., Belgium
Completed

Thu, 10 Nov 2005 12:00:00 EST

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

Condition:   Healthy
Interventions:   Drug: Palbociclib alone;   Drug: Palbociclib + Rabeprazole
Sponsor:   Pfizer
Completed

Wed, 07 Aug 2013 12:00:00 EDT

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects

Condition:   Gastroesophageal Reflux
Interventions:   Drug: Omeprazole;   Drug: Rabeprazole;   Drug: Lactose
Sponsor:   Nantes University Hospital
Completed

Thu, 03 Jun 2010 12:00:00 EDT

A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive

Condition:   GERD
Intervention:   Drug: Rabeprazole sodium
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Completed

Fri, 05 Sep 2008 12:00:00 EDT

Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea

Condition:   Gastroesophageal Reflux
Intervention:   Drug: Rabeprazole Sodium
Sponsor:   Janssen Korea, Ltd., Korea
Completed

Mon, 23 Nov 2009 12:00:00 EST

Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

Condition:   Peptic Ulcer Disease
Interventions:   Other: Hou Gu Mi Xi;   Other: Placebo;   Drug: Rabeprazole
Sponsors:   Jiangxi University of Traditional Chinese Medicine;   Jiangxi Hospital of Traditional Chinese Medicine;   The First Affiliated Hospital of Nanchang University;   Second Affiliated Hospital of Nanchang University;   The Third Affiliated Hospital of Nanchang University;   Nanchang Hongdu Hospital of Traditional Chinese Medicine;   Nanchang Hospital of Integrated Traditional Chinese and Western Medicine;   The Nanchang Third Hospital;   Xinyu People's Hospital;   Xinyu Hospital of Traditional Chinese Medicine;   Jiujiang No.1 People's Hospital;   Jiujiang Hospital of Traditional Chinese Medicine
Recruiting

Wed, 25 Oct 2017 12:00:00 EDT

The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism

Condition:   Calcium Metabolism Disorders
Intervention:   Drug: Rabeprazole or Esomeprazole or Lanzoprazole
Sponsors:   American University of Beirut Medical Center;   AstraZeneca
Completed

Tue, 08 Jun 2010 12:00:00 EDT

Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: High-dose dual therapy (rabeprazole, amoxicillin);   Drug: Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate);   Drug: Amoxicillin-Metronidazole Bismuth quadruple therapy
Sponsors:   National Taiwan University Hospital;   Ministry of Science and Technology, Taiwan
Recruiting

Mon, 01 Apr 2019 12:00:00 EDT

Concomitant Therapy of H. Pylori

Condition:   Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention:   Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Sponsors:   The Catholic University of Korea;   Bucheon St. Mary's Hospital;   St. Vincent's Hospital-Manhattan
Unknown status

Wed, 14 Aug 2013 12:00:00 EDT

Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

Conditions:   Helicobacter Pylori Infection;   Early Gastric Cancer;   Endoscopic Resection
Interventions:   Drug: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin;   Drug: Placebo, Omeprazole or Rabeprazole, Clarithromycin
Sponsor:   National Cancer Center, Korea
Active, not recruiting

Thu, 02 Apr 2015 12:00:00 EDT

Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Condition:   Gastroesophageal Reflux
Interventions:   Other: Non-Pharmacologic Treatment;   Drug: Rabeprazole
Sponsor:   Janssen-Cilag, S.A.
Terminated

Mon, 06 Aug 2007 12:00:00 EDT

A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days);   Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Sponsor:   Shandong University
Unknown status

Wed, 05 Sep 2018 12:00:00 EDT

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

Conditions:   Mantle Cell Lymphoma;   COVID-19
Interventions:   Drug: Acalabrutinib Treatment A;   Drug: Acalabrutinib Treatment B;   Drug: Acalabrutinib Treatment C;   Drug: Acalabrutinib Treatment D
Sponsors:   AstraZeneca;   Parexel
Completed

Fri, 25 Sep 2020 12:00:00 EDT

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

Condition:   Healthy Volunteer
Interventions:   Drug: GDC-0980;   Drug: rabeprazole
Sponsor:   Genentech, Inc.
Completed

Tue, 01 Feb 2011 12:00:00 EST

10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole Sodium 20mg;   Drug: Clarithromycin 500mg;   Drug: Amoxicillin 500 Mg
Sponsor:   Indonesia University
Unknown status

Fri, 28 Apr 2017 12:00:00 EDT

Clinical Trial to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin

Condition:   Healthy
Interventions:   Drug: Metformin;   Drug: Metformin and Pantoprazole;   Drug: Metformin and Rabeprazole
Sponsor:   Seoul National University Hospital
Completed

Mon, 20 May 2013 12:00:00 EDT

Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

Conditions:   Gastric Ulcer;   Duodenal Ulcer
Intervention:   Other: No Intervention
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 22 Apr 2015 12:00:00 EDT

A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: Anaprazole Sodium enteric-coated tablet;   Drug: Placebo;   Drug: Active controlled (rabeprazole)
Sponsor:   Sihuan Pharmaceutical Holdings Group Ltd.
Completed

Wed, 15 Jul 2020 12:00:00 EDT

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Condition:   Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Interventions:   Drug: E3810;   Drug: Teprenone
Sponsor:   Eisai Co., Ltd.
Completed

Tue, 19 Jul 2011 12:00:00 EDT

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Conditions:   Drug-drug Interaction;   Autoimmune Diseases;   Fibrotic Disease
Interventions:   Drug: Belumosudil;   Drug: Itraconazole;   Drug: Rabeprazole;   Drug: Rifampicin;   Drug: Omeprazole
Sponsors:   Kadmon Corporation, LLC;   Quotient Sciences
Completed

Mon, 21 May 2018 12:00:00 EDT

Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Intervention:   Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Sponsor:   Shandong University
Unknown status

Mon, 06 Aug 2018 12:00:00 EDT

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Condition:   Healthy
Intervention:   Drug: rabeprazole
Sponsor:   Eisai Co., Ltd.
Completed

Fri, 12 Mar 2010 12:00:00 EST

A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)

Condition:   Healthy
Intervention:   Drug: rabeprazole
Sponsor:   Eisai Co., Ltd.
Completed

Fri, 12 Mar 2010 12:00:00 EST

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Condition:   Solid and Hematological Malignancies
Interventions:   Drug: Capivasertib;   Drug: Rabeprazole
Sponsors:   AstraZeneca;   Parexel
Recruiting

Wed, 30 Jun 2021 12:00:00 EDT

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: Proton pump inhibitor (rabeprazole)
Sponsor:   Samsung Medical Center
Unknown status

Fri, 05 Oct 2007 12:00:00 EDT

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Condition:   Refractory Reflux Esophagitis
Intervention:   Drug: E3810
Sponsor:   Eisai Co., Ltd.
Completed

Fri, 10 Oct 2008 12:00:00 EDT

Effect of Proton Pump Inhibitors on Palpitations

Condition:   Signs and Symptoms
Interventions:   Drug: Rabeprazole sodium;   Drug: Pacebo
Sponsor:   Jordan Collaborating Cardiology Group
Completed

Mon, 11 Jul 2016 12:00:00 EDT

Improvement in Bronchial Asthma in Patients With Extraesophageal Reflux After Acid Suppression

Conditions:   Bronchial Asthma;   Gastroesophageal Reflux
Intervention:   Drug: Rabeprazole
Sponsors:   Ponce Gastroenterology Research;   PriCara, Unit of Ortho-McNeil, Inc.
Completed

Thu, 06 Oct 2005 12:00:00 EDT

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Condition:   Healthy
Interventions:   Drug: Dasatinib;   Drug: Dasatinib plus Rabeprazole;   Drug: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Sponsors:   University of California, San Francisco;   Genentech, Inc.
Completed

Wed, 20 Jul 2011 12:00:00 EDT

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Condition:   Duodenal Ulcer,DU
Interventions:   Drug: Anaprazole Sodium;   Drug: Rabeprazole sodium
Sponsor:   Sihuan Pharmaceutical Holdings Group Ltd.
Completed

Fri, 07 Aug 2020 12:00:00 EDT

Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation

Condition:   Cardio-cerebrovascular Disease
Interventions:   Drug: Low-dose PPI (Rabeprazole sodium);   Drug: High-dose PPI (Rabeprazole sodium);   Drug: Non-PPI (Gefarnate)
Sponsors:   Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan;   Gastro-Intestinal Medical Care Research Center
Completed

Mon, 18 Jan 2010 12:00:00 EST

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Condition:   Healthy Volunteers
Interventions:   Drug: Glasdegib;   Other: High Fat, High Calorie Meal;   Drug: Rabeprazole
Sponsor:   Pfizer
Completed

Wed, 26 Apr 2017 12:00:00 EDT

A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study

Condition:   Chest Pain
Intervention:   Drug: Rabeprazole 20mg twice daily
Sponsors:   Hospital Authority, Hong Kong;   The University of Hong Kong
Unknown status

Thu, 16 Aug 2007 12:00:00 EDT

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: Reference capsule GDC-0134;   Drug: Prototype capsule GDC-0134;   Drug: rabeprazole
Sponsors:   Genentech, Inc.;   Quotient Clinical
Completed

Wed, 02 Aug 2017 12:00:00 EDT

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Condition:   Healthy
Interventions:   Drug: Ritonavir-boosted Atazanavir;   Drug: Ritonavir-boosted Atazanavir plus Rabeprazole;   Drug: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Sponsor:   University of California, San Francisco
Completed

Thu, 03 Jan 2013 12:00:00 EST

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Condition:   Healthy Volunteer
Interventions:   Drug: fluconazole;   Drug: itraconazole;   Drug: rabeprazole;   Drug: vismodegib
Sponsor:   Genentech, Inc.
Completed

Mon, 21 Jan 2013 12:00:00 EST

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

Condition:   Postnasal Drainage
Intervention:   Drug: Rabeprazole 20 mg twice a day for 90-day period treatment
Sponsors:   Medical College of Wisconsin;   Ortho-McNeil, Inc.;   Eisai Inc.
Completed

Tue, 20 Sep 2005 12:00:00 EDT

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Conditions:   Bioavailability;   B-cell Lymphoid Cancer
Interventions:   Drug: Treatment A- Part 1;   Drug: Treatment B- Part 1;   Drug: Treatment C - Part 1;   Drug: Treatment D- Part 1;   Drug: Treatment A-Part 2;   Drug: Treatment B - Part 2;   Drug: Treatment C - Part 2;   Drug: Treatment D - Part 2
Sponsors:   AstraZeneca;   Acerta Pharma, LLC
Completed

Mon, 27 Jul 2020 12:00:00 EDT

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: Rabeprazole
Sponsor:   Eisai Co., Ltd.
Completed

Fri, 09 May 2014 12:00:00 EDT

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: GDC-0941;   Drug: rabeprazole
Sponsor:   Genentech, Inc.
Completed

Wed, 21 Oct 2009 12:00:00 EDT

Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: H pylori eradication;   Other: H pylori eradication timing
Sponsor:   National Taiwan University Hospital
Unknown status

Fri, 14 Oct 2016 12:00:00 EDT

A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Omeprazole 20mg;   Drug: Esomeprazole 20mg;   Drug: Rabeprazole Sodium 20mg;   Drug: Vonoprazan
Sponsor:   Changi General Hospital
Recruiting

Tue, 09 Apr 2019 12:00:00 EDT

Effect of Inhibitors of the Proton Pump on Intestinal Transporters

Condition:   Healthy
Interventions:   Drug: Dabigatran;   Drug: Rabeprazole and Dabigatran;   Drug: Omeprazole and Dabigatran
Sponsor:   Centre Hospitalier Universitaire de Saint Etienne
Completed

Fri, 14 Aug 2015 12:00:00 EDT

Safety of Rabeprazole in Patients Under Multiple Treatments

Conditions:   Gastroesophageal Reflux;   Gastric Ulcer
Intervention:   Drug: Rabeprazol
Sponsor:   Janssen-Cilag, S.A.
Terminated

Mon, 06 Aug 2007 12:00:00 EDT

To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

Conditions:   Gastroesophageal Reflux Disease;   GERD;   Reflux Esophagitis
Intervention:   Drug: esomeprazole 20 mg
Sponsors:   AstraZeneca;   Parexel
Completed

Tue, 19 Jul 2011 12:00:00 EDT

Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis

Conditions:   Liver Cirrhosis;   Peptic Ulcer
Interventions:   Drug: Proton-pump inhibitor;   Drug: Propranolol+Proton-pump inhibitor
Sponsor:   Taipei Veterans General Hospital, Taiwan
Terminated

Mon, 28 Oct 2019 12:00:00 EDT

Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis

Condition:   Helicobacter Pylori Infection
Interventions:   Diagnostic Test: Histology,13C urea breath test,Stool antigen test,Serological antibody test for H.pylori and Serologic test with a current infection marker of H.pylori;   Drug: Rabeprazole,Minocycline,Amoxicillin and Colloidal bismuth pectin
Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting

Fri, 11 Jun 2021 12:00:00 EDT

Study of BIIB091 Modified Release Formulations in Healthy Participants

Condition:   Healthy Volunteers
Interventions:   Drug: BIIB091;   Drug: Rabeprazole;   Drug: Itraconazole
Sponsor:   Biogen
Recruiting

Fri, 25 Sep 2020 12:00:00 EDT

Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: 10d bismuth quadruple therapy;   Drug: 14d hybrid therapy;   Drug: 14D high-dose dual therapy
Sponsor:   Kaohsiung Veterans General Hospital.
Recruiting

Wed, 19 Dec 2018 12:00:00 EST

To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

Condition:   Heartburn
Intervention:   Drug: esomeprazole 40 mg
Sponsors:   AstraZeneca;   Quintiles, Inc.
Completed

Tue, 30 Nov 2010 12:00:00 EST

Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

Conditions:   Coronary Artery Disease;   Percutaneous Coronary Intervention;   Acute Coronary Syndrome;   Myocardial Infarction
Interventions:   Drug: PPI;   Drug: P-CAB 25;   Drug: P-CAB 50
Sponsor:   Duk-Woo Park, MD
Recruiting

Thu, 04 Jun 2020 12:00:00 EDT

Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: 5RA-5RCM;   Drug: 5RA-5RCT;   Drug: 10RCA
Sponsor:   Buddhist Tzu Chi General Hospital
Completed

Tue, 10 Apr 2012 12:00:00 EDT

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Conditions:   Pharmacokinetics;   Bioavailability
Interventions:   Drug: Acalabrutinib Treatment A;   Drug: Acalabrutinib Treatment B;   Drug: Acalabrutinib Treatment C
Sponsors:   AstraZeneca;   Acerta Pharma, LLC
Completed

Wed, 17 Jun 2020 12:00:00 EDT

Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole;   Drug: Bismuth potassium citrate;   Drug: Metronidazole;   Drug: Amoxicillin
Sponsor:   Shanghai Zhongshan Hospital
Recruiting

Mon, 14 Dec 2020 12:00:00 EST

Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease

Condition:   Gastroesophageal Reflux Disease
Interventions:   Other: symptom questionaire;   Procedure: pH monitoring;   Procedure: Tri-modal imaging endoscopy;   Drug: rabeprazole
Sponsor:   Chinese PLA General Hospital
Unknown status

Fri, 06 Jan 2012 12:00:00 EST

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

Condition:   Healthy
Interventions:   Drug: palbociclib commercial free base;   Drug: famotidine;   Drug: rabeprazole;   Drug: antacid
Sponsor:   Pfizer
Completed

Thu, 27 Mar 2014 12:00:00 EDT

Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Saccharomyces boulardii;   Drug: Placebo
Sponsor:   Clinical Centre of Serbia
Unknown status

Tue, 25 Jun 2019 12:00:00 EDT

Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

Condition:   Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions:   Drug: 10RAC+acetylcystein;   Drug: 10RAC+metronidazole
Sponsor:   Buddhist Tzu Chi General Hospital
Unknown status

Fri, 06 Apr 2012 12:00:00 EDT

Helicobacter Pylori and Proton Pump Inhibitor

Condition:   Helicobacter Infections
Intervention:   Drug: PPI (proton pump inhibitor)
Sponsor:   Asan Medical Center
Completed

Thu, 21 May 2015 12:00:00 EDT

Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment

Condition:   Peptic Ulcer
Intervention:   Procedure: Endoscopy of upper GI tract
Sponsor:   University of Athens
Completed

Mon, 24 Sep 2007 12:00:00 EDT

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Condition:   Non-alcoholic Fatty Liver Disease
Interventions:   Drug: Dabigatran Etexilate;   Drug: Rabeprazol sodium
Sponsor:   Boehringer Ingelheim
Completed

Mon, 08 May 2017 12:00:00 EDT

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: GDC-0134;   Drug: Placebo;   Drug: Rabeprazole;   Drug: Midazolam;   Drug: Caffeine
Sponsor:   Genentech, Inc.
Completed

Thu, 14 Jan 2016 12:00:00 EST

Tetracycline Versus Doxycycline for HP Rescue Therapy

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole;   Drug: Bismuth potassium citrate;   Drug: Metronidazole;   Drug: Doxycycline;   Drug: Tetracycline
Sponsor:   Shanghai Zhongshan Hospital
Recruiting

Tue, 24 Aug 2021 12:00:00 EDT

The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Clarithromycin 500mg;   Drug: Amoxicillin 500mg;   Drug: Tinidazole 500mg;   Drug: Rabeprazole 20mg
Sponsors:   Kirby Institute;   University of Medicine 2, Yangon, Myanmar
Completed

Fri, 18 Oct 2019 12:00:00 EDT

Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay

Condition:   30 Healthy People
Intervention:   Drug: Clopidogrel and proton pump inhibitors
Sponsors:   National Taiwan University Hospital;   Haemonetics Corporation
Unknown status

Wed, 02 Dec 2009 12:00:00 EST

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Condition:   Healthy Subjects
Interventions:   Drug: BOS172767 tablets;   Drug: BOS172767 liquid capsules;   Drug: BOS172767 micronized capsules;   Drug: BOS172767 immediate release capsules;   Drug: BOS172767 matching placebo capsules;   Drug: BOS172767 matching placebo tablets;   Drug: Rabeprazole
Sponsor:   Boston Pharmaceuticals
Completed

Tue, 13 Mar 2018 12:00:00 EDT

A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease

Condition:   Non-erosive Gastroesophageal Reflux Disease
Interventions:   Drug: E3810;   Drug: Placebo
Sponsor:   Eisai Co., Ltd.
Completed

Wed, 14 Sep 2005 12:00:00 EDT

Tailored Juice-guided Eradication Therapy

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: susceptibility-guided therapy;   Drug: empirical clarithromycin-based triple therapy
Sponsor:   Kaohsiung Medical University
Completed

Mon, 19 Aug 2019 12:00:00 EDT

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

Conditions:   Helicobacter Pylori Infection;   Chronic Gastritis
Interventions:   Drug: Berberine;   Drug: Vonoprazan;   Drug: Amoxicillin;   Drug: Rabeprazole;   Drug: Bismuth;   Drug: Clarithromycin
Sponsor:   Xijing Hospital of Digestive Diseases
Not yet recruiting

Fri, 20 Aug 2021 12:00:00 EDT

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole;   Drug: Bismuth potassium citrate;   Drug: Metronidazole;   Drug: Clarithromycin;   Drug: Levofloxacin
Sponsor:   Shanghai Zhongshan Hospital
Recruiting

Thu, 26 Aug 2021 12:00:00 EDT

Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: high dose dual therapy;   Drug: concomitant therapy
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Unknown status

Wed, 22 Dec 2010 12:00:00 EST

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

Condition:   Helicobacter Pylori Eradication Rate
Interventions:   Drug: Modified non-clarithromycin triple therapy;   Drug: Sequential therapy
Sponsor:   Shandong University
Completed

Wed, 18 May 2016 12:00:00 EDT

Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection

Condition:   Rescue Therapy for Helicobacter Pylori
Interventions:   Drug: RBLF;   Drug: RA
Sponsor:   Shanghai Jiao Tong University School of Medicine
Completed

Wed, 06 Mar 2013 12:00:00 EST

Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Gemifloxacin-based triple therapy;   Drug: Standard triple therapy
Sponsor:   Samsung Medical Center
Unknown status

Mon, 23 Feb 2015 12:00:00 EST

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

Condition:   Hypothyroidism;Postablative
Interventions:   Drug: levothyroxine sodium capsule;   Drug: Proton pump inhibitor;   Drug: Levothyroxine Sodium Tablets
Sponsor:   IBSA Institut Biochimique SA
Completed

Wed, 29 Mar 2017 12:00:00 EDT

Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

Condition:   COVID-19
Intervention:   Other: No intervention (Retrospective Cohort Observational)
Sponsors:   Seoul National University Hospital;   Dong-A ST Co., Ltd.
Not yet recruiting

Thu, 08 Apr 2021 12:00:00 EDT

PPI-amoxicillin for H. Pylori Treatment

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole;   Drug: Bismuth potassium citrate;   Drug: Metronidazole;   Drug: Amoxicillin
Sponsor:   Shanghai Zhongshan Hospital
Recruiting

Fri, 20 Aug 2021 12:00:00 EDT

An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide

Condition:   Death, Sudden, Cardiac
Intervention:   Drug: No intervention
Sponsor:   Janssen Research & Development, LLC
Completed

Thu, 25 Jul 2013 12:00:00 EDT

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

Conditions:   Non-erosive Reflux Disease;   Barrett's Esophagus
Interventions:   Device: Ryodoraku;   Device: ANSWatch;   Device: UGI endoscopy;   Other: GerdQ;   Drug: PPI
Sponsor:   Taichung Tzu Chi Hospital
Unknown status

Thu, 29 May 2014 12:00:00 EDT

Tailored Therapy for Helicobacter Pylori in Children

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Tailored Group;   Drug: Standard group
Sponsor:   Beijing Children's Hospital
Unknown status

Fri, 18 Dec 2015 12:00:00 EST

Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection

Conditions:   Helicobacter Pylori Infection;   Compliance, Patient;   Drug Resistance;   Antibiotics
Interventions:   Diagnostic Test: Helicobacter pylori PCR test;   Diagnostic Test: CLO test
Sponsor:   Inha University Hospital
Unknown status

Mon, 04 Dec 2017 12:00:00 EST

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Condition:   Gastroesophageal Reflux Disease (GERD)
Intervention:   Drug: Dexrabeprazole 10 mg Enteric-Coated Tablets
Sponsor:   Neutec Ar-Ge San ve Tic A.Ş
Completed

Wed, 24 Feb 2016 12:00:00 EST

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Conditions:   Gastroesophageal Reflux Disease (GERD);   Community-acquired Pneumonia
Interventions:   Drug: esomeprazole;   Drug: omeprazole;   Drug: pantoprazole;   Drug: lansoprazole;   Drug: rabeprazole;   Drug: cimetidine;   Drug: ranitidine;   Drug: famotidine;   Drug: nizatidine;   Drug: niperotidine;   Drug: roxatidine;   Drug: ranitidine bismuth citrate;   Drug: lafutidine;   Drug: cimetidine combinations;   Drug: famotidine combinations
Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR)
Completed

Tue, 22 Sep 2015 12:00:00 EDT

Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication

Condition:   Helicobacter Infection
Interventions:   Drug: high dose dual therapy;   Drug: sequential therapy;   Drug: clarithromycin-based triple therapy;   Drug: levofloxacin-based triple therapy
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Completed

Thu, 15 Jul 2010 12:00:00 EDT

Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

Conditions:   Gastric Cancer;   Helicobacter Pylori Infection;   Bismuth
Interventions:   Drug: Bismuth potassium citrate containing quadruple therapy;   Drug: Colloidal pectin bismuth capsules containing quadruple therapy;   Drug: Colloidal pectin bismuth particles A quadruple therapy;   Drug: Colloidal pectin bismuth particles B quadruple therapy
Sponsor:   Xijing Hospital of Digestive Diseases
Completed

Tue, 24 Dec 2019 12:00:00 EST

Helicobacter Pylori Eradication and Follow-up

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Rabeprazole;   Drug: Bismuth potassium citrate;   Drug: Metronidazole;   Drug: Clarithromycin;   Drug: Levofloxacin;   Drug: Amoxicillin;   Drug: Doxycycline;   Drug: Tetracycline
Sponsor:   Shanghai Zhongshan Hospital
Recruiting

Thu, 30 Sep 2021 12:00:00 EDT

CANHelp Working Group Treatment Trials

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Standard Triple;   Drug: Sequential;   Drug: Quadruple
Sponsors:   University of Alberta;   Alberta Innovates Health Solutions;   ArcticNet;   Canadian Institutes of Health Research (CIHR)
Completed

Tue, 22 Oct 2013 12:00:00 EDT

Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment

Condition:   Gastroesophageal Reflux Disease (GERD)
Interventions:   Procedure: Transoral Incisionless Fundoplication;   Drug: Proton Pump Inhibitors; active control
Sponsors:   University of Pittsburgh;   EndoGastric Solutions;   Sandhill Scientific;   Crospon
Terminated

Fri, 06 Mar 2009 12:00:00 EST

Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer

Condition:   Gastric Cancer
Interventions:   Drug: Helicobacter pylori eradication;   Drug: placebo
Sponsor:   National Cancer Center, Korea
Completed

Tue, 27 Oct 2009 12:00:00 EDT

Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection

Condition:   Helicobacter Pylori Infection
Intervention:   Drug: Second-line quadruple therapy with endonase
Sponsor:   Chuncheon Sacred Heart Hospital
Terminated

Wed, 18 Jul 2012 12:00:00 EDT

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: IW-3718;   Drug: Matching Placebo;   Drug: PPI
Sponsor:   Ironwood Pharmaceuticals, Inc.
Completed

Tue, 22 Dec 2015 12:00:00 EST

Prophylaxis for Aspiration of Gastric Contents.

Condition:   Pulmonary Aspiration of Gastric Contents
Interventions:   Drug: Drug either PPIS or H2RA and prokinetics;   Procedure: orogastric intubation
Sponsor:   King Saud University
Completed

Wed, 09 Mar 2016 12:00:00 EST

Eradication Rates of Helicobacter Pylori and Its Affecting Factors

Condition:   Helicobacter Infections
Intervention:   Drug: PPI triple therapy
Sponsor:   Seoul National University Bundang Hospital
Completed

Wed, 14 Aug 2013 12:00:00 EDT

Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: Cefuroxime containing bismuth quadruple treatment;   Drug: Classic bismuth quadruple treatment
Sponsor:   Shanghai East Hospital
Not yet recruiting

Mon, 25 Jan 2021 12:00:00 EST

Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding

Condition:   Variceal Bleeding, Endoscopic Variceal Ligation
Intervention:   Device: Wilson-Cook four shooter saeed multi-band ligator
Sponsors:   Kaohsiung Veterans General Hospital.;   Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC;   National Yang-Ming University, Kaohsiung, Taiwan, ROC
Completed

Tue, 12 Mar 2013 12:00:00 EDT

Symptom Assessment for GERD Patients Receiving H. Pylori Eradication

Condition:   Gastroesophageal Reflux Disease
Intervention:  
Sponsor:   National Taiwan University Hospital
Unknown status

Mon, 29 Nov 2010 12:00:00 EST

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Condition:   Extensive-stage Small Cell Lung Cancer
Interventions:   Drug: AL3810;   Drug: carboplatin + etoposide;   Drug: Placebo
Sponsor:   Haihe Biopharma Co., Ltd.
Recruiting

Wed, 05 Feb 2020 12:00:00 EST

Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);   Drug: one proton pump inhibitor, colloidal bismuth pectin;   Drug: two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
Sponsor:   Shandong University
Completed

Wed, 05 Sep 2018 12:00:00 EDT

A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication

Conditions:   Gastric Cancer;   Helicobacter Pylori Infection;   Bismuth
Intervention:   Drug: Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
Sponsor:   Xijing Hospital of Digestive Diseases
Enrolling by invitation

Wed, 09 Dec 2020 12:00:00 EST

Clarithromycin Resistant Tailored Therapy

Conditions:   Peptic Ulcer;   Helicobacter Pylori Infection
Interventions:   Procedure: 23S rRNA point mutation test of Helicobacter pylori;   Procedure: UBT test & Gastroenterology with biopsy c silver stain
Sponsors:   Jin Il Kim;   Korean College of Helicobacter and Upper Gastrointestinal Research
Completed

Mon, 17 Oct 2011 12:00:00 EDT

A New System for GERD Diagnosis and Treatment

Condition:   GERD
Interventions:   Procedure: Stretta;   Procedure: Laparoscopic Nissen fundoplication;   Drug: Probiotic Agent;   Drug: PPI;   Drug: Prokinetic Motility Agents;   Drug: Neuromodulators
Sponsor:   Capital Medical University
Unknown status

Thu, 26 Jul 2018 12:00:00 EDT

Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection

Condition:   Helicobacter Pylori Infection
Interventions:   Drug: susceptibility guided therapy;   Drug: personal medication history guided therapy;   Drug: salvage treatment for failed eradication
Sponsor:   Shandong University
Recruiting

Thu, 21 Jun 2018 12:00:00 EDT

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Condition:   Gastroesophageal Reflux Disease
Interventions:   Drug: arbaclofen placarbil-Cohort 1;   Drug: Placebo-Cohort 5;   Drug: arbaclofen placarbil-Cohort 2;   Drug: arbaclofen placarbil-Cohort 3;   Drug: arbaclofen placarbil-Cohort 4;   Drug: PPI
Sponsor:   XenoPort, Inc.
Completed

Wed, 16 Sep 2009 12:00:00 EDT

Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)

Condition:   Healthy Volunteers
Interventions:   Drug: dacomitinib fasted;   Drug: dacomitinib fed;   Drug: dacomitinib+antacid
Sponsor:   Pfizer
Completed

Mon, 08 Oct 2012 12:00:00 EDT

Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial

Condition:   Liver Cirrhosis
Interventions:   Drug: Placebo;   Drug: Esomeprazole 20mg
Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   German Federal Ministry of Education and Research;   University Hospital Heidelberg
Recruiting

Thu, 25 Jun 2020 12:00:00 EDT